Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome

Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02126553	Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission	completed	Phase 2	29	M.D. Anderson Cancer CenterOTHER	1	Nov 14, 2022	clinicaltrials
NCT01168219	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	completed	Phase 2	68	National Cancer Institute (NCI)NIH	1	Aug 4, 2022